Dermal Filler Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Dermal Filler Market in 2025 is estimated at USD 6.83 billion. The global market size was around USD 6.36 billion in 2024 and is likely to expand at a CAGR of more than 9.3%, surpassing USD 20.21 billion revenue by 2037. North America retains the largest share, supported by economic stability and a rise in cosmetic procedures.
The market growth is attributed to the increasing number of surgical and non-invasive cosmetic procedures around the world. There are several medical conditions, such as fat loss during HIV treatment and acne scars, which require similar interventions to be restored. As per a study released by NLM in November 2022, lipodystrophy effects were observed among 10% to 80% of the total HIV patient population worldwide. On the other hand, the WHO reported that approximately 39.9 million people around the globe were living with HIV in 2023. Another 2023 NLM article concluded that 47.0% of global acne patients suffered from scars, whereas the overall acne prevalence in the world was found to be 20.5% in 2024 (Journal of the American Academy of Dermatology).
Additionally, the worldwide escalating prevalence of early skin aging is propelling the market revenue. These injectables can improve physical features of the face and body to restore dermal volume and diminish wrinkles and other facial lines on the skin, thereby giving the patient a more youthful appearance. Therefore, surging demand for youthful skin, scar removal, and other aesthetic restorations are conjugately propelling demand in this sector. Currently, manufacturers are focusing on developing more durable products, including hyaluronic acid-based gel, to offer a wide variety of options to consumers. This can be testified by the estimations made by the SYMATESE Group while making their debut with the EVOLYSSE collection in 2025, mentioning the size of the U.S. hyaluronic acid derma filler industry to be USD 1.6 billion.
Dermal Filler Sector: Growth Drivers and Challenges
Growth Drivers
- Skin-tightening treatment acceptance among aging people: In developed countries, facial rejuvenation is becoming increasingly popular among people over 50 years of age. According to NLM, the global cosmetic surgery industry was valued at USD 63.4 billion in 2021, which is projected to exhibit a CAGR of 9.6% between 2022 and 2030. It also mentioned that the worldwide merchandise of noninvasive aesthetic treatment is poised to expand at a CAGR of 15.40% from 2023 to 2030. Subsequently, the aging generation is becoming increasingly enticed to opt for non-surgical alternatives for maintaining youthful appearances and following anti-aging trends, which is expected to drive the dermal fillers market.
- Rising personal disposable income: As personal and disposable income rise across the world, the expenditure on the market increases. With the additional earnings, habitats tend to be involved in out-of-pocket spending for aesthetic restorations. For instance, private consumption in India rose to USD 2.1 trillion in 2024. The number of citizens with a USD 10,000.0 annual personal income was over 60.0 million, which is predicted to reach 165.0 million by 2030: IBEF. A similar is also observed in other developed and under-development countries, referring to the heightening volume of investors in this field.
Challenges
- High expenditure associated with procedures: Affordability is always a factor of disruption in any type of aesthetic merchandise. Despite the rising popularity and out-of-pocket expenditure, the expensiveness of these procedures is still a major restriction in the market, particularly in price-sensitive regions. In addition, the worldwide presence of financial inequality, particularly in developing countries such as China and India, often creates difficulty in complete market penetration. This might discourage new entrants and investors from engaging their assets in this field.
Dermal Filler Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.3% |
|
Base Year Market Size (2024) |
USD 6.36 billion |
|
Forecast Year Market Size (2037) |
USD 20.21 billion |
|
Regional Scope |
|
Dermal Filler Segmentation
Materials (Calcium Hydroxylapatite, Hyaluronic Acid, Poly-L-lactic Acid, PMMA, Fat, Others)
Based on materials, the calcium hydroxylapatite segment is anticipated to capture the largest share in the dermal filler market by 2037. Its dominance is attributable to the widespread use of soft tissue fillers for aesthetic restoration, coupled with an increase in procedures involving this regimen. On this note, a worldwide survey was conducted by the International Society of Aesthetic Plastic Surgery (ISAPS) in 2022 on cosmetic procedures. The results revealed that the global number of procedures involving calcium hydroxylapatite was 350,716 in 2022, increasing by 20.9% from 2021 and 171.8% from 2018. These figures testify to the segment’s proprietorship over other types of filler materials.
Product (Biodegradable, Non-Biodegradable)
In terms of product, the non-biodegradable segment is gaining traction in the dermal filler market and is expected to garner notable revenue over the assessed period. This segment is becoming a first-line preference for candidates seeking natural-looking results, stimulation of collagen production, and controlled degeneration. In addition, the manufacturers are also setting their goals in attaining maximum sustainability in their pipeline, making these products more popular across the globe. For instance, in 2022, hyaluronic acid-based filling was the 2nd most performed non-surgical aesthetic procedure in the world, accounting for 4,312,037, up by 15.6% from 2018 (ISAPS survey).
Our in-depth analysis of the global dermal filler market includes the following segments:
|
Materials |
|
|
Product |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDermal Filler Industry - Regional Synopsis
North American Market Forecast 
The North America dermal filler market is predicted to dominate the global landscape by capturing the majority revenue share by the end of 2037. The region’s leadership is backed by an economically stable population, along with a higher percentage of cosmetic surgeries in the region. The number of non-surgical cosmetic procedures in the U.S. was counted to be over 15.0 million in 2020, as per NLM. Another 2022 ISAPS statistic positioned the U.S. on top in performing aesthetic surgeries, accounting for 7.4 million. Moreover, the popularity of dermal fillers among the aging population and the rise in R&D expenditures are projected to fuel the market growth in the region.
Several driving factors in the U.S. present promising business opportunities for the market, such as aesthetic awareness, the aging population, increased personal income, and broad treatment options. As of June 2024, the nationwide personal income witnessed a monthly increment of USD 50.0 billion, where consumer spending increased by USD 57.6 billion: Bureau of Economic Analysis. The demography is inspiring domestic pioneers to expand their reach in this marketplace. For instance, in March 2024, Allergan Aesthetics attained FDA approval for marketing its hyaluronic acid (HA) dermal filler, JUVÉDERM VOLUMA XC injection, for use in the temple region.
APAC Market Forecast 
Asia Pacific is anticipated to register a remarkably fast CAGR in the dermal filler market during the forecast timeline. Technological advancements and rising exposure in dermatology are propelling this region’s progress. The lucrative trading environment is further attracting global leaders to participate in this landscape. For instance, in December 2024, Alma Lasers made its debut in APAC by launching its subsidiary in Thailand. The company previously attained marketing approval from the Thailand Food and Drug Administration (TFDA) for its Profhilo in April. The dermal bio-remodeler is used in remodeling laxity and supporting dermal tissue repair in acne scars.
India is propagating the market with its growing economy and expanding pharmaceutical industry. The increased disposal income of citizens in this country is influencing them to spend more on personal well-being, including their aesthetic desires. This is fostering a large consumer base for global and domestic pioneers. Following this opportunity, in September 2024, Menarini Group expanded its aesthetics portfolio, including Definisse Core Filler, in India. This international extension was a part of the company’s strategy to captivate greater cash flow by addressing the unique needs of the nation’s habitats.
Companies Dominating the Dermal Filler Landscape
- Allergen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merz Pharma
- Sinclair Pharma
- Galderma Laboratories
- BioPlus Co., Ltd.
- Candela Corporation
- BIOXIS pharmaceuticals
- Suneva Medical
- SCULPT Luxury Dermal Fillers Ltd
- Dr. Korman Laboratories Ltd.
- Evolus Inc.
Key players in the market are now focusing on bringing more sustainable and less-toxic solutions, such as hyaluronic acid-based products. They are also producing long-acting embellishments to support optimum performance from their offerings. This is helping them acquire consumer trust and solidify their leadership in this merchandise. For instance, in June 2023, Galderma attained FDA approval for its hyaluronic acid filler, Restylane Eyelight, to treat undereye hollows in adults over 21. The new dermal filler is formulated with NASHA Technology to deliver water-resistance and natural-looking results. Such innovations are inspiring other competitors to create more innovative solutions. This cohort of players includes:
In the News
- In February 2025, Evolus received approval from the FDA to commercialize its EVOLYSSE FORM and EVOLYSSE SMOOTH injectable hyaluronic acid (HA) gels in the U.S. market. This debut of next-generation filler, developed by SYMATESE, is predicted to generate USD 700.0 million worth of net revenue by 2028.
- In January 2025, Galderma introduced its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress. The company shared results from the phase IIIb RELAX trial on Relfydess (RelabotulinumtoxinA), testifying to its long-term efficacy and high patient satisfaction.
Author Credits: Radhika Pawar
- Report ID: 2275
- Published Date: Apr 23, 2025
- Report Format: PDF, PPT
